Oruka Therapeutics
ORKA
17 hedge funds and large institutions have $3.2M invested in Oruka Therapeutics in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 7 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 1
94% more call options, than puts
Call options by funds: $271K | Put options by funds: $140K
0.23% less ownership
Funds ownership: 0.73% → 0.51% (-0.23%)
3% less capital invested
Capital invested by funds: $3.29M → $3.2M (-$94K)
15% less funds holding
Funds holding: 20 → 17 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$325K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$218K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$206K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$203K |
| 5 |
Morgan Stanley
New York
|
+$161K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$824K |
| 2 |
Goldman Sachs
New York
|
-$121K |
| 3 |
JF
Jump Financial
Chicago,
Illinois
|
-$48K |
| 4 |
VF
Virtu Financial
New York
|
-$34.9K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$28K |
ORKA Hedge Fund Activity: Q1 2021 in Review
17 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q1 2021, worth a combined $3.2M — down 2.9% from $3.29M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ORKA and 4 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 6 added.
The largest buyer was Susquehanna International Group, adding an estimated $325K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $824K sold.
- 17 institutional investors held Oruka Therapeutics (ORKA) as of Q1 2021, down from 20 in Q4 2020.
- Funds reported $3.2M of Oruka Therapeutics stock for Q1 2021, down 2.9% quarter-over-quarter.
- 4 funds opened new Oruka Therapeutics positions in Q1 2021 and 7 closed out, a net change of -3 holders.
- The largest Oruka Therapeutics buyer in Q1 2021 was Susquehanna International Group, an estimated $325K added.
- The largest Oruka Therapeutics seller in Q1 2021 was Renaissance Technologies, an estimated $824K sold.
Based on aggregated 13F filings for Q1 2021.